Understanding Cancer Survival and Recurrence Rates

The Global Picture - Cancer Is Growing

The numbers are sobering. In 2022, there were approximately 20 million new cancer cases and 9.7 million cancer deaths worldwide, with 53.5 million people alive within five years of a diagnosis. By 2050, over 35 million new cases per year are projected, a 77% increase.

Australia has one of the highest age-standardised cancer incidence rates in the world, 462.5 per 100,000 (including non-melanoma skin cancer). In 2024, approximately 169,500 Australians were diagnosed with cancer and around 52,700 died from it. Almost 1 in 2 Australian men and women will be diagnosed with cancer by age 85.

The good news? Five-year survival in Australia has improved from 55% (1991–1995) to 71% (2016–2020). But this improvement creates a paradox - more survivors means a larger population living with the risk of recurrence. https://ncci.canceraustralia.gov.au/outcomes/relative-survival-rate/5-year-relative-survival-diagnosis

How Common Is Cancer Recurrence?

Recurrence rates vary enormously depending on cancer type, stage at diagnosis, and treatment received. Here’s what the research shows

Glioblastoma
Estimated recurrence: ~90% within 2 years.​

Ovarian cancer
Estimated recurrence: 70–85%.

Lung cancer
Estimated recurrence: 30–75% (varies by subtype and stage).​

Soft tissue sarcoma
Estimated recurrence: ~50% (approaches 100% in late-stage disease).​

Bladder cancer
Estimated recurrence: ~50% after surgery.​

Pancreatic cancer
Estimated recurrence: 36% within 1 year post-surgery.​

Cervical cancer
Estimated recurrence: ~35%.​

Breast cancer (overall)
Estimated recurrence: ~30%; triple-negative breast cancer has the highest recurrence risk.

Colorectal cancer (Stage III)
Estimated recurrence: roughly 25–33% within 5 years, depending on colon vs rectal and exact cohort.

Prostate cancer
Estimated recurrence: 20–30% within 5 years (often detected by rising PSA).​

Hodgkin's lymphoma
Estimated recurrence: 10–13% after primary treatment; 20–50% after second-line treatment.​

These figures come largely from clinical trial and large-institution cohorts, patients who are typically younger and healthier than the general cancer population. The true rates in everyday practice are likely higher, especially given the limitations in recurrence reporting discussed later.

Colorectal Cancer - Australia’s Growing Crisis

Bowel cancer deserves special attention. It is the deadliest cancer for Australians aged 25–54, and Australia now has the highest rates of early-onset bowel cancer in the world.

Key facts:

• The risk of being diagnosed with bowel cancer before age 40 has more than doubled since 2000.​

• There has been a 266% increase in bowel cancer incidence in adolescents and young adults (15–24 years) over the past three decades.​

• Bowel cancer rates are 2–3 times higher among Australians born in the 1990s compared to those born in the 1950s.​

• Early-onset colorectal cancer rose from 7.6% of all CRC diagnoses in 1992 to 11.1% in 2021.​

• Around 81.9% of early-onset CRC cases are diagnosed at Stage III or IV, largely because younger patients fall outside traditional screening age brackets.​

The Australian government has lowered the National Bowel Cancer Screening Program start age from 50 to 45, but participation is only around 41.7% of eligible Australians. This leaves a large number of high-risk individuals undetected until later stages.​

When colorectal cancer recurs and metastasises, most commonly to the liver, the prognosis is poor:

• More than 50% of CRC patients have or will develop metastasis, most often to the liver.​

• After liver resection for colorectal liver metastases, 50–75% of patients develop further recurrence within two years.

• Median overall survival after recurrence with distant metastasis is about 29 months for single-site recurrence, but just 13 months when distant and locoregional recurrence occur together.​

• In Australia, 5-year relative survival for Stage IV bowel cancer is only 13.4%.

A large international analysis showed that 5‑year recurrence rates have declined over time with better treatment, from 26.9% (2004–2008) to 15.8% (2014–2019) and that recurrence risk falls below 0.5% at 6 years post-surgery. Even so, for many patients, recurrence remains the defining challenge.

"They Always Tell You They've Got It All - But They Never Do"

These words came from a distinguished professor of endocrinology in Sydney, not an oncologist, but a scientist whose clinical observation cuts to the heart of cancer recurrence.

Modern molecular science now validates this observation.

Minimal Residual Disease - The Invisible Threat

Minimal residual disease (MRD) refers to cancer cells that persist after treatment but are undetectable by standard imaging or screening. These cells are the seeds of recurrence.​

Key MRD insights:

• After lung cancer surgery, circulating tumour DNA (ctDNA) has a half-life of roughly 35 minutes.​

• Any ctDNA detected 3 days after surgery indicates ongoing residual disease.​

• In stage II colorectal cancer, ctDNA-based MRD identifies the 10–15% of patients who still harbour residual cancer after apparently curative surgery.​

• Across multiple solid tumours, detectable MRD is strongly associated with a higher risk of recurrence and shorter recurrence‑free survival.​

Dormant Cancer Cells - The Long Game

Perhaps most striking: circulating tumour cells and disseminated tumour cells have been detected in breast cancer survivors decades after primary treatment. Late recurrences 20–40 years after diagnosis are documented.

These disseminated tumour cells can:

• Remain dormant (non‑dividing) for years or decades.

• Evade immune detection and survive chemotherapy and radiation.​

• Reactivate when microenvironmental or immune conditions change, leading to aggressive recurrence.

The clinical reality aligns with the professor’s observation: surgeons may achieve clear margins on pathology, but submicroscopic cancer cells routinely persist.

Cancer Stem Cells - The Central Drivers of Recurrence

Cancer stem cells (CSCs) are increasingly recognised as pivotal drivers of tumour recurrence and treatment resistance.

A comprehensive 2025 systematic review found that:

• Conventional treatments kill the bulk of tumour cells.

• CSCs often survive and can re‑initiate tumours after treatment.

• CSCs drive relapse through latent, therapy‑resistant states.​

CSCs resist treatment through:

• Chromatin remodelling and epigenetic plasticity, maintaining stemness and drug resistance.​

• Non‑canonical signalling and immune evasion (e.g., Wnt5a–CREB1–BACH1, PD‑L1 upregulation, STING suppression).​

• Metabolic reprogramming and mitochondrial adaptation.​

• Escape from apoptosis (cell death) and incomplete differentiation.​

• Epithelial‑to‑mesenchymal transition (EMT), which increases invasiveness and chemoresistance.​

The review concluded that effective cancer control must include CSC‑targeted strategies. This is precisely where most conventional treatments are weakest and where annatto tocotrienol vitamin E becomes highly relevant.​

How Effective Is Conventional Treatment at Preventing Recurrence?

Surgery

Surgery is often essential for solid tumours, but it rarely eliminates all cancer cells. “Clear margins” only mean no cancer cells were seen at the resected edges under the microscope, not that the body is free of all malignant cells.

Factors that increase recurrence risk after surgery include:

• Late‑stage diagnosis.

• Aggressive tumour biology.

• Micrometastases already present at distant sites (especially in Stage III CRC).​

• Cancer stem cells and MRD remaining after surgery.​

Chemotherapy

Helpful but Limited and Sometimes Paradoxical

Adjuvant chemotherapy reduces recurrence risk but does not eliminate it:

• In breast cancer, adjuvant chemotherapy improved 5‑year disease‑free survival from 57% to 69%.​

• Dose‑dense chemotherapy (every 2 weeks instead of 3) reduced recurrence by 14% and breast cancer mortality by 15% over 10 years.​

• In some early breast cancer groups, chemo plus endocrine therapy led to 93% freedom from distant recurrence at 5 years.​

However, research also shows a paradox:

• High‑dose, maximum‑tolerated chemotherapy can cause surrounding fibroblasts to release ELR+ chemokines that actually promote tumour regrowth and aggressiveness.​

• These signals can convert neighbouring cancer cells into tumour‑initiating cells, enhance blood vessel formation, and recruit immune‑suppressing cells.​

• In contrast, metronomic (low‑dose, frequent) chemotherapy avoids this stromal activation and may be more effective at preventing recurrence in some cancers.​

Targeted Therapies and Immunotherapy

Modern therapies have improved outcomes for specific cancers:

• In HER2‑positive early breast cancer, the antibody‑drug conjugate T‑DM1 achieved ~97% freedom from invasive cancer at 5 years in a high‑risk group.​

• PARP inhibitors and anti‑angiogenic drugs significantly prolong progression‑free survival in select molecular subtypes.​

But even with these advances, recurrence remains a major issue in many cancers, especially glioblastoma, ovarian, pancreatic and metastatic CRC.

The Data Problem - How Reliable Are Recurrence Statistics?

Here's something most people, including many clinicians, don't realise: cancer recurrence is not routinely collected in cancer registries.

In Australia:

• New cancer diagnoses are legally notifiable and registries are robust for incidence and mortality.

• But recurrence is not systematically tracked and large population datasets generally do not contain recurrence fields.​

In major international datasets:

• A US study showed hospitals had incomplete recurrence information for 56.7–66.7% of patients when registry data were checked against clinical records.​

• Coders disagreed on whether events were recurrences or new primaries in 25.5–40.8% of cases.​

• Recurrence data missingness has improved over time but still ranges around 6.6–9.3% and remains of mixed quality.​

• Claims‑based algorithms to infer recurrence have “substantial limitations.”

The implication: published recurrence figures are best estimates, not precise counts, and likely underestimate the true burden, especially for late recurrences.

Evidence‑Based Prevention - What Actually Works

Physical Activity

The Strongest Lifestyle Lever

The evidence for structured exercise in reducing recurrence is now compelling:

• A meta‑analysis of 15,000+ patients found that higher physical activity after diagnosis was associated with about a 45% reduction in recurrence risk across several cancer types.​

• Among women with breast cancer, exercise reduced recurrence by 24% and mortality by 45%.​

• Among patients with Stage III colon cancer, exercise reduced recurrence by 40% and mortality by 63%.​

• A 17‑year multinational study led by the University of Sydney found that structured exercise reduced colon cancer recurrence by 28% and death by 37%. After 8 years, 90% of exercise participants were alive compared with 83% of controls.​

These numbers place exercise alongside surgery and chemotherapy as a core component of standard care for many cancers.

Diet and Lifestyle

Strict adherence to cancer prevention recommendations, plant‑rich diet, limited alcohol and sugar, regular exercise, no smoking, healthy weight, is associated with lower recurrence and mortality in high‑risk breast cancer and other cancers.

Key lifestyle actions:

• Emphasise vegetables, fruits, fibre and healthy fats.

• Minimise ultra‑processed foods and sugar‑sweetened beverages.

• Avoid tobacco entirely.

• Maintain a healthy waist circumference and metabolic profile.

MRD Monitoring and Follow‑Up

Circulating tumour DNA (ctDNA) and other MRD tools are transforming follow‑up care:

• MRD‑positive patients have much higher relapse risk and shorter recurrence‑free survival.

• MRD testing can detect recurrence months before imaging or clinical symptoms.​

• Over time, MRD may guide personalised decisions about when to escalate or de‑escalate therapy.​

Patients can discuss ctDNA/MRD monitoring options with their oncologists as part of a comprehensive recurrence‑prevention strategy.

Annatto Delta‑Tocotrienol Targeting What Conventional Treatment Misses

Why This Isn’t “Just Vitamin E”

The large vitamin E trials that failed to prevent cancer (e.g., SELECT) used alpha‑tocopherol, not tocotrienols. Tocotrienols, particularly delta‑tocotrienol (δ‑T3), differ structurally and functionally:​

• Annatto seeds (Bixa orellana) are a unique source of ~90% delta‑tocotrienol and 10% gamma‑tocotrienol with no alpha‑tocopherol, which is important because alpha‑tocopherol can blunt tocotrienol absorption and efficacy.​

Multi‑Pathway Anti‑Cancer Activity

Tocotrienols and delta‑tocotrienol in particular, act on multiple cancer pathways simultaneously:

• Inhibit NF‑κB - a central inflammatory and cancer‑promoting pathway.

• Suppress angiogenesis - via downregulating VEGF and MMP‑9.

• Induce apoptosis - through caspase activation, Bcl‑2 family modulation and upregulation of tumour‑suppressive microRNAs.

• Cause cell‑cycle arrest - e.g., via p27Kip1‑dependent mechanisms in pancreatic cancer.​

• Reverse drug resistance - via effects on P‑glycoprotein.

• Reverse EMT - restoring epithelial characteristics and reducing invasive potential.​

The Critical Point - Delta‑Tocotrienol Targets Cancer Stem Cells

This is where δ‑T3 stands out in the context of recurrence:

Pancreatic cancer
δ‑T3 selectively inhibited pancreatic cancer stem‑like cells, reducing their viability, self‑renewal, stemness genes (Oct4, Sox2), migration, invasion, EMT markers and angiogenesis markers.

Melanoma
δ‑T3 specifically targeted the CSC subpopulation of melanoma cells. Cells that escaped δ‑T3 were unable to form melanospheres, while cells that escaped standard drug vemurafenib showed enhanced stemness.​

Prostate cancer
δ‑T3 suppressed prostate cancer stem‑like cell survival under hypoxic conditions, primarily via inactivation of HIF‑1α signalling.​

Hepatocarcinoma
δ‑T3 activated autophagic cell death pathways in human hepatocarcinoma, supporting anti‑tumour effects.​

By targeting CSCs directly, δ‑T3 addresses the root engine of recurrence that conventional treatments largely leave behind.

Strong Evidence for Colorectal Cancer

A 2024–2025 body of work, including a Monash‑linked review, focused specifically on gamma and delta tocotrienols in colorectal cancer (CRC):

Key CRC‑specific findings:

• δ‑T3 and γ‑T3 inhibit proliferation and induce apoptosis in multiple CRC cell lines (HCT‑116, HT‑29, Caco‑2, SW480, SW620, SW837, DLD‑1, HCT8).

• δ‑T3 suppressed the Wnt/β‑catenin pathway, reducing β‑catenin, Wnt‑1, cyclin D1, c‑Jun, and MMP‑7 in colon cancer cells, crucial because Wnt signalling is aberrantly activated in >90% of CRCs and drives CSC self‑renewal.

• Tocotrienol‑rich fraction suppressed colon cancer growth in mouse xenografts via Wnt pathway inhibition.​

• Annatto tocotrienol suppressed colitis‑associated CRC progression via TLR4 signalling in mouse models.​

• δ‑T3 and its metabolite improved beneficial gut bacteria (e.g., Lactococcus, Bacteroides) and reduced pro‑inflammatory cytokines and carcinogenesis in a colon cancer model.​

• When combined with capecitabine (a standard CRC chemotherapy), γ‑T3 enhanced apoptosis and reduced metastasis‑related proteins, suggesting synergistic potential.​

Taken together, CRC may be one of the cancer types where annatto tocotrienol is particularly relevant for recurrence‑focused strategies.

Clinical Evidence - The Moffitt Phase I Trial

The first human trial of δ‑T3 was conducted at the H. Lee Moffitt Cancer Center in patients with pancreatic neoplasia:

• 25 patients received oral δ‑T3 (200–3,200 mg/day) for 13 days before surgery.

• Safety: Well tolerated at all doses; no dose‑limiting toxicity. Only one mild, drug‑related adverse event (grade 1 diarrhoea) at the highest dose.​

• Biological effectiveness: At 800 mg/day, 80% of patients showed significant induction of apoptosis in their neoplastic cells, measured by cleaved caspase‑3 staining.​

• Selectivity: δ‑T3 induced apoptosis in pre‑malignant and malignant cells but not in adjacent normal pancreatic tissue.​

• Pharmacokinetics: Human plasma levels at the higher doses matched levels that were effective in preclinical models.​

Ongoing trials include:

• SIPP‑T3: δ‑T3 to prevent progression of pancreatic intraductal papillary mucinous neoplasms (IPMNs).

• TOCANNATO: annatto δ‑T3 in women with primary breast cancer prior to surgery, assessing oxidative stress, inflammation, immune markers, and Ki‑67.

Geranylgeraniol (GG) - The Complementary Partner

Geranylgeraniol (GG) is a diterpene alcohol and key intermediate in the mevalonate pathway, which produces cholesterol, steroid hormones, and isoprenoids needed for protein prenylation (e.g., Ras, Rho GTPases).

GG‑related findings:

• GG accelerates ubiquitination and degradation of HMG‑CoA reductase, the rate‑limiting enzyme of the mevalonate pathway, the same enzyme targeted by statins, but through a different mechanism.​

• GG modulates prenylation of small GTPases involved in cancer cell signalling and survival.​

• Its oxidative metabolite, geranylgeranoic acid (GGA), has demonstrated chemopreventive effects against hepatocellular carcinoma.​

• GG supports apoptosis and reduces oxidative stress in various cell models.

The Synergy - δ‑T3 + GG Together

A key study on human DU145 prostate cancer cells showed:

• δ‑T3 and GG together produced synergistic inhibition of cancer cell growth (combination index 0.67–0.75).

• The combination, but not the individual compounds at those doses, induced G1 cell‑cycle arrest.

• Mechanistically, δ‑T3 + GG synergistically downregulated HMG‑CoA reductase and reduced membrane K‑Ras.

This synergy occurs because:

• δ‑T3 promotes degradation of HMG‑CoA reductase protein.

• GG feeds back on the same pathway to enhance this degradation signal.

• Together, they more effectively suppress the mevalonate pathway, depriving cancer cells (including CSCs) of key growth signals.

Integrating the Evidence - A Framework for Recurrence Prevention

Target: Bulk tumour cells
Conventional approach: Surgery plus chemotherapy and/or radiation
Limitation: Effective at debulking, but residual cells and micrometastases often remain.
Role for δ‑T3/GG: δ‑T3 induces selective apoptosis in neoplastic cells while sparing normal tissue.​

Target: Cancer stem cells
Conventional approach: Limited direct targeting; many therapies inadvertently enrich CSCs.
Limitation: CSCs survive treatment and re‑initiate tumours, driving recurrence and metastasis.
Role for δ‑T3/GG: δ‑T3 directly targets CSCs in pancreatic, melanoma, prostate, and liver cancer models.

Target: EMT and invasion
Conventional approach: Some anti‑metastatic strategies, but no consistent CSC/EMT focus.
Limitation: EMT enables invasion, metastasis, and chemoresistance.​
Role for δ‑T3/GG: δ‑T3 reverses EMT markers, reduces migration and invasion, and downregulates metastasis‑related proteins.

Target: Mevalonate pathway
Conventional approach: Statins to lower cholesterol and indirectly impact cancer risk.
Limitation: Compensatory upregulation of HMG‑CoA reductase; side effects limit high‑dose use.​
Role for δ‑T3/GG: δ‑T3 + GG synergistically suppress HMG‑CoA reductase, reduce K‑Ras signalling, and modulate protein prenylation.

Target: Angiogenesis
Conventional approach: Anti‑VEGF agents and other anti‑angiogenic drugs.
Limitation: Resistance and escape pathways often develop.
Role for δ‑T3/GG: δ‑T3 inhibits VEGF and MMP‑9, reducing blood vessel formation that tumours need to grow.

Target: Chronic inflammation / NF‑κB
Conventional approach: Non‑specific anti‑inflammatories and lifestyle advice.
Limitation: Often not targeted at tumour microenvironment; cancer‑related inflammation persists.
Role for δ‑T3/GG: δ‑T3 inhibits NF‑κB and reduces pro‑inflammatory cytokines; GG mitigates oxidative stress.

Target: Tumour microenvironment
Conventional approach: Limited direct modulation, apart from some immunotherapies.
Limitation: High‑dose chemotherapy can activate stromal cells to promote recurrence.​
Role for δ‑T3/GG: δ‑T3’s anti‑inflammatory and anti‑angiogenic effects, plus GG’s antioxidant actions, may help normalise the microenvironment.

Target: Dormant cells / MRD
Conventional approach: Surveillance (imaging, blood tests); no standard therapy focused on dormant disseminated cells.
Limitation: Dormant cells remain below detection thresholds yet can reactivate years later.
Role for δ‑T3/GG: By targeting CSCs and the mevalonate pathway, δ‑T3 + GG may help weaken the machinery that dormant cells rely on, an area where more research is needed.

A Practical Framework for Reducing Recurrence Risk

Target area: Physical activity
Why it matters: Consistently associated with 28–45% reductions in recurrence and mortality in breast and colon cancer.
What to do: Aim for at least 150 minutes per week of moderate‑intensity exercise (e.g., brisk walking), plus strength work 2–3 times per week, ideally guided by your oncology team or exercise physiologist.

Target area: Diet and lifestyle
Why it matters: Inflammation, insulin resistance, and obesity are linked to higher recurrence risk.
What to do: Emphasise plants, fibre and healthy fats; minimise ultra‑processed foods and sugar; avoid smoking; maintain a healthy waist circumference.

Target area: Cancer stem cells
Why it matters: CSCs are central drivers of recurrence and metastasis.
What to do: Discuss emerging CSC‑targeted strategies with your clinician; consider evidence‑informed nutraceuticals such as annatto δ‑tocotrienol (as a complement, not replacement, to medical care).

Target area: Mevalonate pathway
Why it matters: Supports proliferation and survival of many cancer cells via cholesterol and isoprenoid synthesis.​
What to do: Where appropriate, discuss statins with your doctor; consider δ‑T3 + GG as complementary support for mevalonate modulation.

Target area: Chronic inflammation and oxidative stress
Why it matters: Creates a pro‑recurrence environment at the cellular level.
What to do: Lifestyle changes, anti‑inflammatory nutrition, stress reduction, adequate sleep; consider δ‑T3 and GG for their anti‑inflammatory and antioxidant effects.

Target area: MRD monitoring
Why it matters: Detects residual disease months before imaging or symptoms.
What to do: Ask your oncologist whether ctDNA or MRD testing is appropriate in your case.

How to Get Both δ‑T3 and GG Conveniently

Eannatto 150+ capsules contain 150 mg of annatto delta‑tocotrienol (DeltaGold®) plus 75 mg of geranylgeraniol (GG‑Gold®) per capsule, delivering both compounds in one convenient dose.

Based on research and expert guidance (including Dr Barrie Tan, who discovered annatto as the richest natural δ‑tocotrienol source):

Option: 1 capsule daily
Daily dose: 150 mg δ‑tocotrienol + 75 mg GG
Best suited for: General antioxidant and cellular protection in otherwise healthy adults.

Option: 2 capsules daily
Daily dose: 300 mg δ‑tocotrienol + 150 mg GG
Best suited for: Adults with a strong focus on recurrence prevention or higher‑risk profiles (to be discussed with their healthcare provider).

Tocotrienol has a relatively short half‑life (~4 hours), so splitting the dose, one capsule with lbreakfast and one with dinner, helps maintain more consistent blood levels throughout the day. Always take with a meal containing some healthy fat for optimal absorption.

Clinical trials have shown δ‑T3 to be safe at doses up to 3,200 mg/day, and annatto tocotrienol (DeltaGold®) has FDA‑affirmed GRAS status and is included in TGA‑listed medicines in Australia.

The Bottom Line

Cancer recurrence is driven by biology, cancer stem cells, minimal residual disease, tumour dormancy and a pro‑inflammatory microenvironment. Surgery and chemotherapy are vital but incomplete; they often leave behind the very cells most capable of bringing the cancer back.

Annatto delta‑tocotrienol is one of the few natural compounds with a substantial and growing evidence base for targeting cancer stem cells, reversing EMT, modulating the Wnt and NF‑κB pathways, and working synergistically with the mevalonate pathway through GG. When combined with structured exercise, a protective lifestyle, and appropriate medical surveillance (including MRD monitoring where available), δ‑T3 + GG offers a rational, science‑aligned way to add another layer of defence against recurrence.

Because the best time to prevent recurrence is before it happens.

This article is based on peer‑reviewed research from institutions including the H. Lee Moffitt Cancer Center, MD Anderson Cancer Center, Monash University, Victoria University, the University of Sydney, and the National Cancer Institute. It is provided for educational purposes only and does not constitute medical advice. Always consult your healthcare provider before making changes to your health regimen, particularly if you are undergoing cancer treatment.

Shop Eannatto 150+ → | Explore Our FAQs →